CVS Health tops Q4 estimates, keeps 2026 guidance

(Sharecast News) - CVS Health beat market forecasts with its fourth-quarter results on Tuesday as the American healthcare, health insurance and pharmacy chain held on to guidance for the current financial year. The firm reported total revenues of $105.7bn for the final three months of 2025, up 8.2% compared with the year before, with growth across all operating segments.

Net income jumped to $2.92bn to $2.30 a share, up from $1.62bn and $1.30 previously. On an adjusted basis, EPS fell to $1.09 from $1.19, but still came in comfortably ahead of the $1.00 consensus forecast.

Full-year revenues increased to a record $402.1bn from $372.8bn, while annual net income swelled to $14.4bn from $12.0bn.

"Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses," said chief executive and president David Joyner.

"From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America."

For 2026, the company reiterated guidance for full-year adjusted EPS of $7.00-7.20, up from $6.75 in 2025. However, cash flow guidance was trimmed to "at least $9bn" from a prior target of $10bn.

CVS Health shares were up 0.7% at $76.30 by 1618 GMT.